Piperacillin/tazobactam: A critical review of the evolving clinical literature

Clinical Infectious Diseases

Volumn 22, Issue 1, 1996, Pages 107-123

  Sanders Jr , W Eugene ^a   Sanders, Christine C ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CILASTATIN; CLAVULANIC ACID; CLINDAMYCIN; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TEICOPLANIN; TICARCILLIN; TOBRAMYCIN;

ABDOMINAL INFECTION; ALLERGIC REACTION; DOSE RESPONSE; DRUG BLOOD LEVEL; FEVER; GASTROINTESTINAL SYMPTOM; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; NEUTROPENIA; PRIORITY JOURNAL; PSEUDOMONAS; RASH; RESPIRATION DEPRESSION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; TACHYCARDIA; URTICARIA;

EID: 0030045596     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.1.107     Document Type: Review

References (67)

1. Livermore DM. Determinants of activity of β-lactamase inhibitor combinations. J Antimicrob Chemother 1993;31(suppl A):9-21.
2. Thomson KS, Weber DA, Sanders CC, Sanders WE Jr. β-lactamase production in members of the family Enterobacteriaceae and resistance to β-lactam-enzyme inhibitor combinations. Antimicrob Agents Chemother 1990;34:622-7.
3. Drusano GL, Schimpff SC, Hewitt WL. The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis 1984;6:13-32.
4. Eliopoulos GM, Moellering RC Jr. Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med 1982;97:755-60.
5. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother 1993;37:851-8.
6. Hedberg M, Lindqvist L, Tunér K, Nord CE. Effect of clavulanic acid, sulbactam and tazobactam on three different β-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum. J Antimicrob Chemother 1992;30:17-25.
7. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I β-lactamases. J Antimicrob Chemother 1990;25:199-208.
8. Appelbaum PC. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria. J Antimicrob Chemother 1993;31(suppl A):29-38.
9. Payne DJ, Cramp R, Winstanley DJ, Knowles DJC. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrob Agents Chemother 1994;38:767-72.
10. Bonfiglio G, Livermore DM. β-lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to β-lactamase inhibitor combinations. J Antimicrob Chemother 1994;33:465-81.
11. Jones RN, Pfaller MA, Fuchs PC, Aldridge K, Allen SD, Gerlach EH. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group stains. Diagn Microbiol Infect Dis 1989;12:489-94.
12. Murray PR, Cantrell HF, Lankford RB and the In Vitro Susceptibility Surveillance Group. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected β-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. Diagn Microbiol Infect Dis 1994;19: 111-20.
13. Fuchs PC, Barry AL. In vitro activity of piperacillin-tazobactam: a review. Complications in Surgery 1993;12(suppl A):22-7.
14. Kitzis MD, Ferré B, Coutrot A, Acar JF, Gutmann L. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria. Eur J Clin Microbiol Infect Dis 1989;8:783-8.
15. Weber DA, Sanders CC. Diverse potential of β-lactamase inhibitors to induce Class I enzymes. Antimicrob Agents Chemother 1990;34: 156-8.
16. Sörgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993; 31(suppl A):39-60.
17. Sorgel F, Kinzig M. Pharmacokinetics and tissue distribution of piperacillin/tazobactam, with particular reference to its potential in abdominal and soft tissue infections. Eur J Surg 1994;160(suppl 573):39-44.
18. Bryson HM, Brogden RN. Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-35.
19. Beecham Laboratories. Timentin package insert. Bristol, Tennessee: Beecham Laboratories, January, 1989.
20. Lederle Piperacillin Inc. Zosyn package insert. Carolina, Puerto Rico: Lederle Piperacillin Inc., October 1993.
21. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 3rd ed. NCCLS document M7-A3. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1993.
22. Testa R. New antimicrobial susceptibility testing information: piperacillin/ tazobactam. Clinical Microbiology Newsletter 1993;15:119-20.
23. Eliopoulos GM, Klimm K, Ferraro MJ, Jacoby GA, Moellering RC Jr. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 1989;12:481-8.
24. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993;32:223-31.
25. McLaughlin JC, Barry AL, Fuchs PC, Gerlach EH, Hardy DJ, Pfaller MA. In-vitro activity of the five β-lactam/β-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 1994;33:223-30.
26. Snydman DR, Cuchural GJ Jr, the National Anaerobic Susceptibility Study Group. Susceptibility variations in Bacteroides fragilis: a national survey. Infectious Disease in Clinical Practice 1994;3(suppl 1):534-43.
27. Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT. Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother 1989;33:1964-9.
28. Eklund A-E, Nord CE, Swedish Study Group. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. J Antimicrob Chemother 1993;31(suppl A):79-85.
29. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-73.
30. Niinikoski J, Havia T, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993;176:255-61.
31. Polk HC Jr, Fink MP, Laverdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. Am Surg 1993;59:598-605.
32. Vestweber K-H, Grundel E. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections. Eur J Surg 1994;160(suppl 573):57-60.
33. Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW, the Piperacillin/Tazobactam Skin and Skin Structure Study Group. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob Agents Chemother 1993; 37:1580-6.
34. Tassler H, Cullmann W, Elhardt D. Therapy of soft tissue infections with piperacillin/tazobactam. J Antimicrob Chemother 1993;31(suppl A): 105-12.
35. Tassler H. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue and in bone and joint infections. Complications in Surgery 1993;12(suppl A):50-60.
36. Gould IM, Ansari A, Harvey G, Douglas JG, Smith CC, Reid TMS. Piperacillin/tazobactam in the treatment of serious acute soft tissue infection. Drugs Exp Clin Res 1991;17:187-90.
37. Sweet RL, Roy S, Faro S, et al. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet Gynecol 1994;83:280-6.
38. Tapp A, Wise B, Cardozo L. Efficacy and safety of piperacillin/tazobactam in gynecological infections. Complications in Surgery 1993;12(suppl A):61-4.
39. Sanders CV. Treatment of polymicrobial gynecologic and skin and skin-structure infections: worldwide clinical trials. Infectious Disease in Clinical Practice 1995;4(suppl 1):S26-32.
40. Shlaes DM, Baughman R, Boylen CT, et al. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection. J Antimicrob Chemother 1994;34: 565-77.
41. Joshi M, Solomkin JS, Bernstein JM, and the Piperacillin/Tazobactam Pneumonia Study Group. Open, randomized multicenter comparison of piperacillin/tazobactam vs ceftazidime, both plus tobramycin, in hospital-acquired lower respiratory tract infections [abstract no 856]. In: Abstract book of the 6th International Congress for Infectious Diseases. Boston, MA: International Society for Infectious Diseases, 1994:274.
42. Mouton Y, Leroy O, Beuscart C, et al. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993;31(suppl A):87-95.
43. Smith DL. Parenteral piperacillin/tazobactam combined with amikacin for the treatment of severe pulmonary infections in intensive care units. Infectious Disease in Clinical Practice 1995;4(suppl 1):S33-6.
44. Nowé P. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Medicine 1994;20(suppl 3):S39-42.
45. Wise R. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia. J Antimicrob Chemother 1993;31(suppl A):97-104.
46. Offenstadt G, Vassal T, Lesage D, Guidet B. Piperacillin/tazobactam treatment of serious infections in an intensive care unit. Complications in Surgery 1993;12(suppl A):65-9.
47. Investigators of the Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Eur J Surg 1994;160(suppl 573): 61-6.
48. Micozzi A, Nucci M, Venditti M, et al. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993;12:1-8.
49. Kelsey SM, Weinhardt B, Pocock CE, Shaw E, Newland AC. Piperacillin/ tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy. J Chemother 1992;4:281-5.
50. Cometta A, Zinner S, De Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445-52.
51. Kuye O, Teal J, DeVries VG, Morrow CA, Tally FP. Safety profile of piperacillin/tazobactam in phase I and III clinical studies. J Antimicrob Chemother 1993;31(suppl A):113-24.
52. Gooding PG, Clark BJ, Sathe SS. Piperacillin: a review of clinical experience. J Antimicrob Chemother 1982;9(suppl B):93-9.
53. Croydon EA, Hermoso C. An evaluation of the safety and tolerance of timentin. J Antimicrob Chemother 1986;17(suppl C):233-40.
54. Campoli-Richards DM, Brogden RN. Sulbactam/ampicillin: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs 1987;33:577-609.
55. Calandra GB, Wang C, Aziz M, Brown KR. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimicrob Chemother 1986;18(suppl E):193-202.
56. Rotstein C, Cimino M, Winkey K, Cesari C, Fenner J. Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients. Am J Med 1988;85(suppl 1A):36-43.
57. Neu HC. Carbenicillin and ticarcillin. Med Clin N Am 1982;66:61-77.
58. Sanders CC, Thomson KS, Bradford PA. Problems with detection of β-lactam resistance among nonfastidious gram-negative bacilli. Infect Dis Clin North Am 1993;7:411-24.
59. Sanders CC, Sanders WE Jr, Thomson KS, Cavalieri SJ. Failure to adopt new interpretive criteria for ticarcillin-clavulanic acid could prove fatal [letter]. Antimicrob Agents Chemother 1992;36:1343.
60. Sanders CC, Iaconis JP, Bodey GP, Samonis G. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 β-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother 1988;32:1365-9.
61. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles I. Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin and tobramycin. DICP 1991;25:1050-7.
62. Van der Auwera P, Duchateau V, Lambert C. Husson M, Kinzig M, Sorgel F. Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid. Antimicrob Agents Chemother 1993;37:1860-8.
63. Donowitz GR. Third generation cephalosporins. Infect Dis Clin North Am 1989;3:595-612.
64. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90.
65. Sanders WE Jr, Sanders CC. Inducible β-lactamases: clinical and epidemiological implications for use of newer cephalosporins. Rev Infect Dis 1988;10:830-8.
66. Anonymous. Piperacillin/tazobactam. Med Lett Drugs Ther 1994;36: 7-9.
67. Davey PG, Vacani P, Parker SE, Malek MM. Assessing cost effectiveness of antimicrobial treatment: monotherapy compared with combination therapy. Eur J Surg 1994;160(suppl 573):67-72.